Extended-Release Once-Daily Formulation of Tofacitinib: Evaluation of Pharmacokinetics Compared With Immediate-Release Tofacitinib and Impact of Food

THU0143 Pharmacokinetics, Bioavailability and Safety of A Modified Release Once Daily Formulation of Tofacitinib in Healthy Volunteers

(2014) M. Lamba et al.   ANNALS OF THE RHEUMATIC DISEASES

Inhibition of JAK kinases in patients with rheumatoid arthritis: scientific rationale and clinical outcomes

(2010) Richard J. Riese et al.   BEST PRACTICE & RESEARCH IN CLINICAL RHEUMATOLOGY

Anti-inflammatory activity and neutrophil reductions mediated by the JAK1/JAK3 inhibitor, CP-690,550, in rat adjuvant-induced arthritis

(2010) Debra M Meyer et al.   Journal of Inflammation-London

Co-administration of the JAK inhibitor CP-690,550 and methotrexate is well tolerated in patients with rheumatoid arthritis without need for dose adjustment

(2009) Stanley Cohen et al.   BRITISH JOURNAL OF CLINICAL PHARMACOLOGY

Oral osmotically driven systems: 30 years of development and clinical use

(2009) Vincent Malaterre et al.   EUROPEAN JOURNAL OF PHARMACEUTICS AND BIOPHARMACEUTICS

Extrudable core system: Development of a single-layer osmotic controlled-release tablet

(2008) Kenneth C. Waterman et al.   JOURNAL OF CONTROLLED RELEASE